KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.

Decroos, A.; Cheminant, M.; Bruneau, J.; Carras, S.; Parinet, V.; Pelletier, L.; Lacroix, L.; Martin, N.; Giustiniani, J.; Lhermitte, L.; Asnafi, V.; Battistella, M.; Lemonnier, F.; De Leval, L.; Sicard, H.; Bonnafous, C.; Gauthier, L.; Genestier, L.; Caruso, S.; Gaulard, P.; Hermine, O.; Ortonne, N.

doi:10.3324/haematol.2022.282220

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.

Details

Download: 11076-Article Text-81046-2-10-20230927.pdf (1064.75 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0

Serval ID

serval:BIB_9494E12B88F0

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.

Journal

Haematologica

Author(s)

Decroos A., Cheminant M., Bruneau J., Carras S., Parinet V., Pelletier L., Lacroix L., Martin N., Giustiniani J., Lhermitte L., Asnafi V., Battistella M., Lemonnier F., De Leval L., Sicard H., Bonnafous C., Gauthier L., Genestier L., Caruso S., Gaulard P., Hermine O., Ortonne N.

ISSN

1592-8721 (Electronic)

ISSN-L

0390-6078

Publication state

Published

Issued date

01/10/2023

Peer-reviewed

Oui

Volume

108

Number

Pages

2830-2836

Language

english

Notes

Publication types: Letter
Publication Status: epublish

Abstract

Not available.

Keywords

Humans, Lymphoma, T-Cell, Peripheral/drug therapy, Lymphoma, T-Cell, Peripheral/genetics, Receptors, KIR3DL2, Lymphoma, T-Cell, Cutaneous, Skin Neoplasms/drug therapy

URN

urn:nbn:ch:serval-BIB_9494E12B88F02

OAI-PMH

oai:serval.unil.ch:BIB_9494E12B88F0

DOI

10.3324/haematol.2022.282220

Pubmed

37165836

Web of science

001109389400039

Open Access

Yes